Does this mean the Kazia phase 2 trial is over?
Kazia’s own phase II study of paxalisib in glioblastoma has completed dosing, with the final
patient on study drug having now experienced disease progression, after approximately 2.3
years on treatment. Kazia will now work with the investigators to bring the study to a
conclusion and to seek publication of final data in a high-quality scientific journal.
